Cargando…

The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance

The four components present in the trypanocidal treatment Samorin, the commercially available formulation of isometamidium, were separated and purified by column chromatography. These compounds as well as the Samorin mixture and the other phenanthridine trypanocide, homidium, were tested on Trypanos...

Descripción completa

Detalles Bibliográficos
Autores principales: Eze, Anthonius A., Igoli, John, Gray, Alexander I., Skellern, Graham G., De Koning, Harry P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356087/
https://www.ncbi.nlm.nih.gov/pubmed/30685630
http://dx.doi.org/10.1016/j.ijpddr.2019.01.003
_version_ 1783391455541198848
author Eze, Anthonius A.
Igoli, John
Gray, Alexander I.
Skellern, Graham G.
De Koning, Harry P.
author_facet Eze, Anthonius A.
Igoli, John
Gray, Alexander I.
Skellern, Graham G.
De Koning, Harry P.
author_sort Eze, Anthonius A.
collection PubMed
description The four components present in the trypanocidal treatment Samorin, the commercially available formulation of isometamidium, were separated and purified by column chromatography. These compounds as well as the Samorin mixture and the other phenanthridine trypanocide, homidium, were tested on Trypanosoma congolense and wild type, diamidine- and isometamidium-resistant Trypanosoma brucei brucei strains using an Alamar blue drug sensitivity assay. EC(50) values obtained suggest that M&B4180A (2) was the most active of the components, followed by M&B38897 (1) in all the strains tested, whereas M&B4596 (4) was inactive. Samorin was found to be significantly more active than any of the individual components alone, against T. congolense and all three T. b, brucei strains. Samorin and all its active constituents displayed reduced activity against the previously characterised isometamidium-resistant strain ISMR1.
format Online
Article
Text
id pubmed-6356087
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63560872019-02-08 The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance Eze, Anthonius A. Igoli, John Gray, Alexander I. Skellern, Graham G. De Koning, Harry P. Int J Parasitol Drugs Drug Resist Article The four components present in the trypanocidal treatment Samorin, the commercially available formulation of isometamidium, were separated and purified by column chromatography. These compounds as well as the Samorin mixture and the other phenanthridine trypanocide, homidium, were tested on Trypanosoma congolense and wild type, diamidine- and isometamidium-resistant Trypanosoma brucei brucei strains using an Alamar blue drug sensitivity assay. EC(50) values obtained suggest that M&B4180A (2) was the most active of the components, followed by M&B38897 (1) in all the strains tested, whereas M&B4596 (4) was inactive. Samorin was found to be significantly more active than any of the individual components alone, against T. congolense and all three T. b, brucei strains. Samorin and all its active constituents displayed reduced activity against the previously characterised isometamidium-resistant strain ISMR1. Elsevier 2019-01-21 /pmc/articles/PMC6356087/ /pubmed/30685630 http://dx.doi.org/10.1016/j.ijpddr.2019.01.003 Text en © 2019 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Eze, Anthonius A.
Igoli, John
Gray, Alexander I.
Skellern, Graham G.
De Koning, Harry P.
The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance
title The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance
title_full The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance
title_fullStr The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance
title_full_unstemmed The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance
title_short The individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance
title_sort individual components of commercial isometamidium do not possess stronger trypanocidal activity than the mixture, nor bypass isometamidium resistance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356087/
https://www.ncbi.nlm.nih.gov/pubmed/30685630
http://dx.doi.org/10.1016/j.ijpddr.2019.01.003
work_keys_str_mv AT ezeanthoniusa theindividualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance
AT igolijohn theindividualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance
AT grayalexanderi theindividualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance
AT skellerngrahamg theindividualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance
AT dekoningharryp theindividualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance
AT ezeanthoniusa individualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance
AT igolijohn individualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance
AT grayalexanderi individualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance
AT skellerngrahamg individualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance
AT dekoningharryp individualcomponentsofcommercialisometamidiumdonotpossessstrongertrypanocidalactivitythanthemixturenorbypassisometamidiumresistance